# Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

> **NCT04973280** · — · COMPLETED · sponsor: **Celgene** · enrollment: 187 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Beta-thalassemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04973280
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-26
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973280, "Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04973280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*